Firm Attends FDA Hearing on Cannabis and Derived Products

  Last Friday, May 31, the U.S. Food and Drug Administration (“FDA”) held their first public hearing regarding cannabis and cannabis-derived products.  Influenced by the recent market boom of hemp and cannabidiol (“CBD”) products, the FDA’s hearing presented an opportunity for industry … Read more about Firm Attends FDA Hearing on Cannabis and Derived Products